CTOs on the Move

RaNA Therapeutics

www.ranarx.com

 
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ranarx.com
  • 790 Memorial Dr Ste 203
    Cambridge, MA USA 02139
  • Phone: 617.945.7361

Executives

Name Title Contact Details

Funding

RaNA Therapeutics raised $55M on 07/23/2015
RaNA Therapeutics raised $51M on 01/11/2017

Similar Companies

Biomedical Implant Technology

Biomedical Implant Technology is a St Catharines, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Body Logic

Body Logic is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virginia Mason Franciscan Health

Virginia Mason Franciscan Health is a health care provider that offers compassionate, quality health care throughout the Pacific Northwest and Puget Sound Area.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.

Xponential

Xponential Fitness, Inc. (NYSE: XPOF) is the largest global franchisor of boutique fitness brands. Through its mission to make boutique fitness accessible to everyone, the Company operates a diversified platform of ten brands spanning across verticals including Pilates, indoor cycling, barre, stretching, rowing, dancing, boxing, running, functional training and yoga. In partnership with its franchisees, Xponential franchisees offer energetic, accessible, and personalized workout experiences led by highly qualified instructors in studio locations across 48 U.S. states and through master franchise agreements or international expansion in 11 additional countries. Xponential Fitness` portfolio of brands includes Club Pilates, the nation`s largest Pilates brand; CycleBar, the nation`s largest indoor cycling brand; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix, the largest franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; STRIDE, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program.